First-in-human study completed
ezCOL performed a first-in-human clinical phase I/IIa study to produce the Proof of Concept (PoC) related to the efficacy and safety of the ezCOL cholesterol-lowering technology involving human volunteers with slightly elevated blood cholesterol (NCT03378999). Participant recruitment started in 2018 and was completed the same year counting 82 volunteers. This first clinical study has been initiated in September 2018 and has been finished in June 2019 at the study site of Maastricht University Medical Center (MUMC).
The continuation of our clinical trials will commence after validation of our preclinical efforts. ezCOL’s lead compound R. rubrum is currently in mid-stage preclinical phase. Upon development of a validated clinical candidate our clinical trails will be continued using R. rubrum biomass.